Article

The Anti-VEGF Aptamer Approach: The Macugen Collaborative Trial

Recent results of clinical trials of the anti-VEGF aptamer Macugen (pegaptanibsodium are extremely promising for patients with choroidal neovascularization,said Carmen Puliafito, MD, MBNA, chairman of the Bascom Palmer Eye Institute,Miami.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Kalaris and AlloVir Inc. complete merger
March 22nd 2025

Kalaris and AlloVir Inc. complete merger

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/Atif)
March 21st 2025

Staying the course in shifting winds

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

How COVID-19 shifted ophthalmologist-patient communication
March 21st 2025

How COVID-19 shifted ophthalmologist-patient communication

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200
March 20th 2025

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

© 2025 MJH Life Sciences

All rights reserved.